ProKidney Corp
NASDAQ:PROK
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.5109
5.18
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
ProKidney Corp
ProKidney Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Winston-Salem, North Carolina and currently employs 0 full-time employees. The company went IPO on 2021-06-30. ProKidney Corp., formerly Social Capital Suvretta Holdings Corp. III, is a clinical-stage biotechnology company. The firm is focused on developing a cell therapy platform capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. Its lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to stabilize or improve kidney function in a CKD patient's diseased kidneys. REACT is a product that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The firm is focused on conducting a Phase III development program and multiple Phase II clinical trials for REACT in subjects with moderate to severe diabetic kidney disease.
ProKidney Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Winston-Salem, North Carolina and currently employs 0 full-time employees. The company went IPO on 2021-06-30. ProKidney Corp., formerly Social Capital Suvretta Holdings Corp. III, is a clinical-stage biotechnology company. The firm is focused on developing a cell therapy platform capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. Its lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to stabilize or improve kidney function in a CKD patient's diseased kidneys. REACT is a product that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The firm is focused on conducting a Phase III development program and multiple Phase II clinical trials for REACT in subjects with moderate to severe diabetic kidney disease.
Phase II Data: ProKidney reported promising interim results from its RMCL-002 Phase II trial, showing REACT cell therapy may help preserve kidney function, especially in high-risk stage 4 CKD patients.
Phase III Protocol Change: The company is modifying its proact 1 Phase III trial to focus on sicker CKD patients (eGFR 20–35 ml/min), based on Phase II findings, and increasing enrollment by 600 patients.
Enrollment & Manufacturing Delays: Enrollment in proact 1 and manufacturing are paused to update protocols and address EU regulatory audit issues, with both expected to resume in the first half of 2024.
Safety Profile: REACT therapy continues to show a safety profile similar to kidney biopsy, with no significant treatment-related serious adverse events reported.
Upcoming Catalysts: Final Phase II (002) results and interim data from the 007 trial are expected in the first half and mid-2024, respectively, providing near-term data catalysts.
Financial Position: Management stated the company is well-capitalized into 2025, with several potential financing catalysts ahead.
